• Kangjian Miaomiao

  Participated · Series B · Jun 2024

  康健苗苗（杭州）医药有限公司, founded in 2014, focuses on the oral-health sector and offers an oral comprehensive platform, dental digitalization systems, and end-to-end dental product customization. The company says it has built a full ecosystem linking dentists and dental clinics. Its legal representative is 林小平, who is also the largest shareholder holding 51.01% of shares. The firm’s registered capital is RMB 14.7036 million. 康健苗苗 has three extant external investments: 汉斯夫（杭州）医学科技有限公司, 袋鼠苗苗（杭州）数据服务有限公司, and 美苗苗（杭州）齿科器械有限公司. Going forward the company plans to upgrade its platform information technology and adapt its services toward more customized offerings. 康健苗苗 operates an oral/dental data services platform built around its e‑commerce channel “梅苗苗” and digital dental solutions. The company has provided online procurement and value‑added services for dental instruments, consumables, drugs and equipment to over 50,000 domestic dental clinics. It has established six logistics centers nationwide, a near‑100‑person R&D team and three digital laboratories to develop dental data products and systems. The firm is developing an AI, big‑data and cloud‑based dental data platform and DaaS system to expand from B2B clinic services toward supporting individual dentists (To D). Future plans include continued R&D and production of digital dental products, medical and data services, and expanding the scale of its e‑commerce business. The company launched in August 2017 and has pursued strategic partnerships, including an exclusive China distribution and supply‑chain cooperation with Korea’s listed DIO.

• Thousand Oaks Biopharmaceuticals

  Participated · Series A · Jan 2019

  Thousand Oaks Biopharmaceuticals (澳斯康) is a CDMO and cell‑culture media biotech focused on integrated CMC biomanufacturing services spanning R&D, process development, production, logistics, technical support and after‑sales. Its affiliate Jianshun Bio (健顺生物) develops and manufactures serum‑free, chemically defined mammalian cell culture media and is described as a leading domestic supplier, serving 100+ clinical projects including over 20 phase‑III trials. On the CDMO side the company has served more than 40 clients since launching that business and reports rapidly growing annual orders. Operational assets include a 10,000 m2 cGMP facility with 2,000L batch and 500L perfusion production capacity and formulation lines for vial filling/lyophilization and pre‑filled syringes/cartridges; the company says it has passed audits to NMPA, FDA and EMA standards. The company states the new funding will be used to expand CDMO and media production capacity and to build a global‑scale media production base and an internationally leading CDMO platform. Thousand Oaks emphasizes an international management and technical team and positions its proprietary serum‑free media as enabling domestic substitution of previously imported products. Thousand Oaks Biopharmaceuticals is a biopharma firm. The company completed a Series B financing, raising 450 million yuan (about $64 million). The round was led jointly by CICC Capital’s sub‑fund CICC Jiatai and CITIC Securities’ private equity arm Goldstone Investment Limited. The article does not disclose the company’s product pipeline or future plans. No operating metrics (revenue, users) or use of proceeds are provided in the report. The financing strengthens the company’s capital base at the Series B stage. TOBIO is an integrated global CMC organization supplying GMP cell culture media and biomanufacturing capabilities. It offers integrated CMC services including cell line development from DNA sequences, process and bioanalytical development, customized cell culture media development, clinical material supply, commercial manufacturing, bioanalytical services and regulatory filings. The company closed a $45 million Series A to advance its phase II CDMO business and to fund construction of large-scale cell culture media (LSCCM) cGMP manufacturing facilities in Haimen, Nantong, China. TOBIO says the new plant will be the world’s largest cell culture medium manufacturing facility and will increase current media production capacity. Management frames the expansion as enabling strategic partnerships to accelerate biologics development from bench to market and to help partners provide affordable and accessible biologics. The company has global footprints in Shanghai, Haimen and Lanzhou in China, and Thousand Oaks and Pleasanton, California.

No current team members are available.